| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo
Cancer Res Treat. 2019;51(1):119-127.   Published online March 12, 2018    DOI: https://doi.org/10.4143/crt.2018.019
                              Supplementary         Cited By 2
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
Cancer Res Treat. 2019;51(1):43-52.   Published online February 14, 2018    DOI: https://doi.org/10.4143/crt.2017.562
                                 Cited By 1
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
Changhoon Yoo, Boram Han, Hyeong Su Kim, Kyu-pyo Kim, Deokhoon Kim, Jae Ho Jeong, Jae-Lyun Lee, Tae Won Kim, Jung Han Kim, Dae Ro Choi, Hong Il Ha, Jinwon Seo, Heung-Moon Chang, Baek-Yeol Ryoo, Dae Young Zang
Cancer Res Treat. 2018;50(4):1324-1330.   Published online January 8, 2018    DOI: https://doi.org/10.4143/crt.2017.526
                              Supplementary         Cited By 1
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo
Cancer Res Treat. 2017;49(2):416-422.   Published online July 28, 2016    DOI: https://doi.org/10.4143/crt.2016.121
                                 Cited By 3
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
Yo-Han Cho, So Young Yoon, Soo-Nyung Kim
Cancer Res Treat. 2017;49(1):255-262.   Published online May 18, 2016    DOI: https://doi.org/10.4143/crt.2015.452
                                 Cited By 2
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
Cancer Res Treat. 2012;44(4):235-241.   Published online December 31, 2012    DOI: https://doi.org/10.4143/crt.2012.44.4.235
                                 Cited By 14
Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat. 2011;43(4):236-243.   Published online December 27, 2011    DOI: https://doi.org/10.4143/crt.2011.43.4.236
                                 Cited By 10
Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
Dal Yong Kim, Dae Ho Lee, Sun-Joo Jang, Sang-We Kim, Cheolwon Suh, Jung Shin Lee
Cancer Res Treat. 2011;43(4):212-216.   Published online December 27, 2011    DOI: https://doi.org/10.4143/crt.2011.43.4.212
                                 Cited By 1
A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
Soon Il Lee, Se Hoon Park, Do Hyoung Lim, Keon Woo Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2011;43(2):96-101.   Published online June 30, 2011    DOI: https://doi.org/10.4143/crt.2011.43.2.96
                              
A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer
Se Hoon Park, Soo Yeon Jeon, Kwang Il Ko, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Ki Lee, Min Chung
Cancer Res Treat. 2006;38(3):121-125.   Published online June 30, 2006    DOI: https://doi.org/10.4143/crt.2006.38.3.121
                              
A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer
Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Res Treat. 2006;38(2):72-77.   Published online April 30, 2006    DOI: https://doi.org/10.4143/crt.2006.38.2.72
                                 Cited By 2
Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line Therapy
Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn
Cancer Res Treat. 2004;36(4):235-239.   Published online August 31, 2004    DOI: https://doi.org/10.4143/crt.2004.36.4.235
                                 Cited By 4
Treatment of Small Cell Lung Cancer
Atsushi Horiike, Nagahiro Saijo
Cancer Res Treat. 2003;35(3):177-180.   Published online June 30, 2003    DOI: https://doi.org/10.4143/crt.2003.35.3.177
      
Irinotecan Combined with Bolus Fluorouracil, Continuous Infusion Fluorouracil, and Low-Dose Leucovorin Every Two Weeks in Patients with Oxaliplatin Pretreated Metastatic Colorectal Cancer
Hyuk Chan Kwon, Sung Hyun Kim, Jae Seok Kim, Hyo Jin Kim
Cancer Res Treat. 2003;35(2):135-140.   Published online April 30, 2003    DOI: https://doi.org/10.4143/crt.2003.35.2.135
         Cited By 4
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Cancer Research and Treatment 2017; 49(4): 915-926.
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community